Kyntra Bio

Kyntra Bio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kyntra Bio (KYNB) as of Oct 20, 2026 is -52.48 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -145.12 M USD — a change of -63.84% (higher).

EBITDA

-52.48 MUSD

YoY

-63.84%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kyntra Bio is 2025 -52.48 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kyntra Bio was 2024 -145.12 M USD. It decreases by -63.84% higher compared to the previous year.

The Kyntra Bio EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-86.69 M USD
Jan 1, 2019
-79.01 M USD
Jan 1, 2020
-181.48 M USD
Jan 1, 2021
-343.93 M USD
Jan 1, 2022
-300.42 M USD
Jan 1, 2023
-322.72 M USD
Jan 1, 2024
-145.12 M USD
Jan 1, 2025
-52.48 M USD
The Kyntra Bio EBITDA history
YEAREBITDAYoY
-52.48 MUSD-63.84%
-145.12 MUSD-55.03%
-322.72 MUSD+7.42%
-300.42 MUSD-12.65%
-343.93 MUSD+89.51%
-181.48 MUSD+129.68%
-79.01 MUSD-8.86%
-86.69 MUSD-29.29%
-122.61 MUSD+128.52%
-53.65 MUSD-30.88%
-77.63 MUSD+54.93%
-50.10 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kyntra Bio Stock analysis

What does Kyntra Bio do? Kyntra Bio Inc is a biopharmaceutical company based in San Francisco, United States, operating within the health care sector. Listed on November 14, 2014, the firm engages in the discovery, development, and commercialization of novel therapeutics. It leverages expertise in hypoxia-inducible factor and connective tissue growth factor biology to create innovative medicines. The company is developing roxadustat for anemia associated with chronic kidney disease, myelodysplastic syndromes, and chemotherapy-induced anemia. Additionally, it is researching pamrevlumab for conditions such as idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy. The organization currently employs 34 people in its operations. Kyntra Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kyntra Bio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kyntra Bio is -52.48 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kyntra Bio changed from -145.12 M USD to -52.48 M USD, representing a -63.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Kyntra Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Kyntra Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Kyntra Bio

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Kyntra Bio